Abstract:In recent years, engineering T cell therapy has made great progress in tumor immunotherapy, which mainly includes T-cell receptor-engineered T cell（TCR-T） therapy and chimeric antigen receptor T cell（CAR-T） therapy. Due to their structure difference, TCR-T and CAR-T cells show different characteristics in signal activation and antigen recognition. CAR has scFv derived from antibody, containing CD3ζ and costimulatory domain（s）, making engineered CAR able to recognize specific tumor associated antigens. Therefore, CAR has an ability to bind unprocessed tumor surface antigens without MHC processing, while TCR engages with both tumor intracellular and surface antigens embedded in MHC. While CAR-T cell therapy has demonstrated a significant clinical effect against malignant blood tumors, TCR-T cell therapies have been tested in hematological and solid tumors. Even though clinical results are encouraging for both approaches, several major challenges have been identified, including: target antigen selection such as less tumor toxicity and antigen escape, T cell homing to the tumor, T cell infiltration into the tumor, T cell persistence, and local immunosuppression in the tumor microenvironment. Synthetic biology technologies have enabled flexible reprogramming of engineered T cells to overcome the aforementioned limitations, bringing new opportunities for improving their safety and effectiveness, but the choice of a suitable target antigen is still a key for success. Moreover, improved preclinical TCR/CAR screening is likely to enhance the safety of engineered T cell therapies, and additional T cell engineering to further enhance engineered T cells at various levels has generated promising results, including:（1） modulation of affinity,（2） safety control elements, and（3） targeting TME components. Future developments will likely harness combinatorial strategies to overcome challenges posed by the tumors. In this article, we address structure and signal activation, target selection, affinity optimization, safety modification and gene editing strategies for engineered T cells, and also review the potential synthetic biological approaches and latest progress of engineered T cell therapy in the application of tumor immunotherapy.

Optical sensing and control of T cell signaling pathways

Exploiting T cell signaling to optimize engineered T cell therapies

Optimization of T Cell Redirecting Strategies: Obtaining Inspirations from Natural Process of T Cell Activation

T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells

Utilizing distinct CAR and TCR signaling to generate enhanced cellular immunotherapy

Optogenetic control of chemokine receptor signal and T-cell migration

CRISPR–Cas9 applications in T cells and adoptive T cell therapies

Co-Stimulatory Receptor Signaling in CAR-T Cells

Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety

Versatile strategy for controlling the specificity and activity of engineered T cells

The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Cellular behavior analysis from live-cell imaging of TCR T cell-cancer cell interactions

Toward high-throughput engineering techniques for improving CAR intracellular signaling domains

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Synthetic biology and engineered T cell therapy

Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy

Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screening and single-cell sequencing

Unlocking the potential of Tregs: innovations in CAR technology

Direct control of CAR T cells through small molecule-regulated antibodies

T cell receptors, mechanosensors, catch bonds and immunotherapy